BioPharm International
June 15, 2003
Columns and Departments
16
6
by BioPharm International staff
June 15, 2003
In Search of the Optimum biotech Strategy
16
6
by Peter Loupos, Aventis Drug Innovation and Approval and Andrew Grygiel A collaborative framework can be a driver for cultural change, encouraging knowledge sharing between internal and external personnel and improving innovation and productivity throughout the enterprise.
June 15, 2003
Detecting and Accounting for Variability
16
6
by Chandrashekar Ganesa, Genzyme Corporation, Brian W. Granda, and Robert J. Mattaliano
June 15, 2003
In Search of the Optimum biotech Strategy
16
6
by Penny Cass, BioPharm International Stay current on the changes in corporate governance regulations ? whether your company is public or private, in the United States or elsewhere. As a capital-intensive industry, many of our third-party associations are going to require that biopharmaceutical companies comply with the new regulations to receive financing. The trend to regulate corporate governance activities hasn't ended ? more rules promulgated by more government entities should be anticipated.
June 15, 2003
In Search of the Optimum biotech Strategy
16
6
by Ellis Wilson, AstraZeneca Pharmaceuticals, James McDonough, William Allbee, and Jann Nielsen Compared with their big pharma counterparts, biotech project managers earn more advanced degrees, have fewer years' experience in the industry, and more frequently classify their role as "senior management."
June 15, 2003
In Search of the Optimum biotech Strategy
16
6
by Bruce Babbitt, PAREXEL International, JanHasker Jonkman, and Paul McKim By partnering with external drug development service providers, small biopharmaceutical start-ups can move their products out of the lab and into clinical development more efficiently.
June 15, 2003
Columns and Departments
16
6
by Jill Wechsler, BioPharm International FDA is examining policy options for incorporating genomic information into the regulatory process while encouraging manufacturers to share pharmacogenomic research.
June 15, 2003
Columns and Departments
16
6
by Desiree de Myer, BioPharm International Despite market conditions favorable to merger and acquisition activity, a frenzy of consolidations still hasn't taken place.